Peptides for Primary Biliary Cholangitis: Immune Modulation

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide-based therapies are emerging as a targeted approach for Primary Biliary Cholangitis, aiming to modulate immune responses and support liver health. These novel interventions offer the potential to precisely dampen the autoimmune attack on bile ducts without broad immunosuppression.

Peptides for Primary Biliary Cholangitis: Modulating Immunity and Promoting Liver Health

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive destruction of the small bile ducts within the liver, leading to cholestasis, inflammation, and eventually cirrhosis. While ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are standard treatments, a significant portion of patients respond inadequately or experience side effects. This unmet need drives research into novel therapeutic strategies, with peptide-based interventions emerging as a promising area, particularly for their immunomodulatory and regenerative capabilities.

Peptide-Based Approaches in Primary Biliary Cholangitis

Peptides offer a targeted approach to PBC by influencing immune responses, reducing inflammation, and supporting liver repair.

1. Immunomodulatory Peptides

• Targeting Autoimmune Responses: The core of PBC is an autoimmune attack. Peptides are being investigated for their ability to induce antigen-specific tolerance, meaning they can specifically dampen the immune response against bile duct cells without broadly suppressing the entire immune system [3]. This is a significant advantage over conventional immunosuppressants.
• pMHCII-based Nanomedicines: Similar to other autoimmune liver diseases, peptide-major histocompatibility complex class II (pMHCII)-based nanomedicines are being explored. These nanomedicines can present specific autoantigenic epitopes to re-educate the immune system, potentially halting the autoimmune destruction of bile ducts [8].

2. Anti-inflammatory and Regenerative Peptides

• BPC-157: This pentadecapeptide, derived from human gastric juice, is known for its powerful healing, anti-inflammatory, and tissue-repairing properties [9, 10, 12]. In PBC, BPC-157 could help reduce the chronic inflammation in the bile ducts and liver parenchyma, potentially slowing disease progression and promoting tissue regeneration.
• KPV: As a tripeptide fragment of alpha-melanocyte stimulating hormone, KPV exhibits potent anti-inflammatory effects [4]. Its ability to modulate inflammatory pathways could be beneficial in reducing the immune-mediated damage characteristic of PBC.
• Thymosin Alpha-1 and Thymosin Beta 4: These peptides are recognized for their roles in immune system modulation and tissue repair. Thymosin Alpha-1 can help balance immune responses, while Thymosin Beta 4 promotes regeneration and reduces inflammation, both of which are crucial in managing chronic liver conditions like PBC [4].

3. Novel Peptide Therapeutics

• Navacim Therapeutics: Preclinical research has shown that Navacim therapeutics, a peptide-based approach, can effectively blunt autoimmune liver diseases, including PBC, without suppressing general immunity [11]. This targeted approach represents a significant advancement in treating autoimmune conditions.

Clinical Outlook and Practical Advice

The development of peptide-based therapies for Primary Biliary Cholangitis is an exciting area of research, offering the potential for more precise and less immunosuppressive treatments. These therapies aim to address the underlying autoimmune pathology and support liver health.

Practical Takeaway

If you have PBC, it is essential to work closely with your hepatologist to manage your condition effectively. While UDCA and OCA remain first-line treatments, staying informed about emerging peptide therapies and discussing their potential role with your doctor can help you explore all available options for optimizing your liver health and quality of life.

References

[1] Mayo Clinic. (2026). Primary biliary cholangitis (PBC) - Diagnosis and treatment. https://www.mayoclinic.org/diseases-conditions/primary-biliary-cholangitis/diagnosis-treatment/drc-20376880
[2] Angelara, M., et al. (2025). Primary biliary cholangitis. Treatment options in 2025. Journal of Clinical Medicine, 14(13), 3324. https://pmc.ncbi.nlm.nih.gov/articles/PMC12620492/
[3] Pugliese, A. (2003). Peptide-based treatment for autoimmune diseases. Journal of Clinical Investigation, 111(10), 1451-1454. https://pmc.ncbi.nlm.nih.gov/articles/PMC154453/
[4] LivvNatural. (n.d.). Autoimmune Conditions and Peptide Therapy: Hope or Hype? https://livvnatural.com/autoimmune-conditions-and-peptide-therapy-hope-or-hype/?srsltid=AfmBOorUA-ZLThsn_xaf-9M90fUNiiKMmHgkw16gOXmlGD09Ovxpfgth
[5] Zhang, L., et al. (2023). Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis. Journal of Clinical and Translational Hepatology, 11(5), 1017-1027. https://www.xiahepublishing.com/2310-8819/JCTH-2022-00408
[6] Lora, D. R. (n.d.). Primary Biliary Cholangitis: New treatment goals and novel salvage therapy. World Gastroenterology Organisation. https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/primary-biliary-cholangitis-new-treatment-goals-and-novel-salvage-therapy
[7] USADA. (n.d.). BPC-157: Experimental Peptide Creates Risk for Athletes. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
[8] Umeshappa, C. S., et al. (2019). Suppression of a broad spectrum of liver autoimmune diseases by peptide-major histocompatibility complex class II-based nanomedicines. Journal of Autoimmunity, 99, 10-21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6517389/
[9] Chang, C. H., et al. (2014). Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules, 19(11), 19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
[10] Beverly Hills Concierge Doctor. (n.d.). BPC-157 Peptide Therapy. https://beverlyhillsconciergedoctor.com/anti-aging-wellness/peptide-therapy/bpc-157/
[11] Parvus Therapeutics. (2019). Parvus Therapeutics Publication of Preclinical Proof-of-Concept Research That Underlies the Development of Navacim Therapeutics for the Treatment of Autoimmune Liver Diseases. https://parvustx.com/parvus-therapeutics-publication-of-preclinical-proof-of-concept-research-that-underlies-the-development-of-navacim-therapeutics-for-the-treatment-of-autoimmune-liver-diseases/
[12] Deek, S. A., et al. (2021). BPC 157 as Potential Treatment for COVID-19. International Journal of Molecular Sciences, 22(21), 11676. https://pmc.ncbi.nlm.nih.gov/articles/PMC8575535/